Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13C-labeled phenylalanine is a stable isotope-labeled form of the essential amino acid L-phenylalanine, where one or more carbon atoms are replaced with the non-radioactive carbon-13 isotope. It is utilized in clinical research as a metabolic tracer to investigate amino acid kinetics, protein turnover, and metabolic pathways without the risks associated with ionizing radiation. By measuring the enrichment of 13C in breath CO2 or blood/urine metabolites following administration, researchers can quantify the rate of phenylalanine oxidation and its incorporation into proteins. In a study conducted by the Institute for Environmental Sciences (jRCT1080223621), it was administered orally to healthy volunteers to evaluate carbon excretion ratios and metabolic fate over a multi-day period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 13C-labeled phenylalanine.